Eli Lilly Reports Sofe-M Ovarian Cancer Data: 79% Response Rate
Eli Lilly announced new clinical data for investigational drug sofetabart mipitecan at the ESMO 2026 Congress in Madrid. The headline reports a 100% disease-control rate.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.